Restlyane® Refyne Injectable Gel
FDA premarket approval P140029/S047 · decided 2022-12-23
Approval details
- PMA number
- P140029
- Supplement
- S047
- Supplement type
- Special (Immediate Track)
- Supplement reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Trade name
- Restlyane® Refyne Injectable Gel
- Generic name
- Implant, dermal, for aesthetic use
- Applicant
- Q-Med AB
- Date received
- 2022-11-21
- Decision date
- 2022-12-23
- Days to decision
- 32 days
- Decision code
- APPR
- Product code
- LMH
- Advisory committee
- General, Plastic Surgery
- Expedited review
- No
- Location
- Uppsala
- Statement
- Approval for revisions to the clinician labeling and patient labeling of Restylane® Refyne Injectable Gel as a result of postmarket surveillance data.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.